Clinical Laboratory Improvement Advisory Committee
This article was originally published in The Gray Sheet
Executive SummaryMeeting will be held May 26-27 at the Centers for Disease Control and Prevention in Atlanta. The committee plans to review the criteria for placing tests in the waived category under the Clinical Laboratory Improvement Amendments of 1988 but will not discuss specific tests. The panel is accepting public comment on the subject until April 30. For further information contact Henry Colvin of the CDC at 404/639-1706.
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.